Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Optinose Inc (NQ: OPTN )

0.9265 -0.0052 (-0.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 209,329
Open 0.9300
Bid (Size) 0.8400 (94)
Ask (Size) 0.9600 (25)
Prev. Close 0.9317
Today's Range 0.9200 - 0.9472
52wk Range 0.8000 - 2.100
Shares Outstanding 53,309,012
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
OPTN Stock Earnings: OptiNose Beats EPS, Misses Revenue for Q2 2024
OPTN stock results show that OptiNose beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire

Performance

YTD
-25.88%
-25.88%
1 Month
-9.17%
-9.17%
3 Month
-16.53%
-16.53%
6 Month
-40.61%
-40.61%
1 Year
-26.76%
-26.76%

More News

Read More
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
From Optinose, Inc.
Via GlobeNewswire
7 Little-Known Penny Stocks That Can Turn $10K Into $1 Million
Via InvestorPlace
OptiNose's Earnings: A Preview
Via Benzinga
Expanded Access to XHANCE with Addition to National Commercial Formularies
From Optinose, Inc.
Via GlobeNewswire
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Optinose, Inc.
Via GlobeNewswire
Why Doximity Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
OPTN Stock Earnings: OptiNose Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces $55 Million Registered Direct Offering
From Optinose, Inc.
Via GlobeNewswire
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why Are Stocks Down Today?
Via InvestorPlace
Why Is OptiNose (OPTN) Stock Up 12% Today?
Via InvestorPlace
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
From Optinose, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Optinose to Present at the Needham Virtual Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
From Optinose, Inc.
Via GlobeNewswire
OPTN Stock Earnings: OptiNose Meets EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Earnings Scheduled For March 7, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.